Evidence map›Paper›PMID 26627455›Full record

ArticleJournal of nanobiotechnology2015

Tumor specific liposomes improve detection of pancreatic adenocarcinoma in vivo using optoacoustic tomography.

Wenyuan Yin, Charles W Kimbrough, Jorge G Gomez-Gutierrez, Christopher T Burns, Phillip Chuong, William E Grizzle, Lacey R McNally

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Advanced iron oxide nanotheranostics for multimodal and precision treatment of pancreatic ductal adenocarcinoma.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Current and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in Oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016
    Review
  17. Article
  18. Theranostic nanoparticles for detection and treatment of pancreatic cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenyuan YinUniversity of Louisville, 505 S Hancock, Louisville, KY, 40202, USA. wenyuan.yin@louisville.edu.
Charles W KimbroughUniversity of Louisville, 505 S Hancock, Louisville, KY, 40202, USA. charles.kimbrough@louisville.edu.
Jorge G Gomez-GutierrezUniversity of Louisville, 505 S Hancock, Louisville, KY, 40202, USA. jorge.gutierrez@louisville.edu.
Christopher T BurnsUniversity of Louisville, 505 S Hancock, Louisville, KY, 40202, USA. christopher.burns@louisville.edu.
Phillip ChuongUniversity of Louisville, 505 S Hancock, Louisville, KY, 40202, USA. phillip.chuong@louisville.edu.
William E GrizzleUniversity of Alabama Birmingham, ZRB 408, 1720 2nd Avenue South, Birmingham, AL, 35294, USA. wgrizzle@uabmc.edu.
Lacey R McNallyUniversity of Louisville, 505 S Hancock, Louisville, KY, 40202, USA. Lrmcna01@louisville.edu.
University of Louisville · USUniversity of Alabama at Birmingham · US

Funding

UAB / UMN SPORE in Pancreatic CancerP50CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUCHSBAUM, DONALD J · 2010 to 2014
$11.1M
Virus adjunctive therapies for pancreatic cancerP20CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BUCHSBAUM, DONALD J. · 2003 to 2007
$4.6M
NCI NIH HHS 2P50CA101955NCI NIH HHS P20 CA101955NCI NIH HHS P50 CA101955
6 · The paper itself

Abstract

backgroundPancreatic cancer often goes undiagnosed until late stage disease due in part to suboptimal early detection. Our goal was to develop a Syndecan-1 tagged liposome containing fluorescent dye as an improved contrast agent for detection of pancreatic adenocarcinoma in vivo using multispectral optoacoustic tomography.

resultsThe diagnostic capabilities and specificity to pancreatic adenocarcinoma of Syndecan-1 targeted liposomes were evaluated both in vitro and in vivo. Immunocytochemistry showed that liposomes preferentially bound to and released their contents into cells expressing high levels of insulin-like growth factor 1 receptor. We determined that the contents of the liposome were released into the cell as noted by the change in propidium iodide fluorescence from green to red based upon nucleic acid binding. In an orthotopic mouse model, the liposomes preferentially targeted the pancreatic tumor with little off-target binding in the liver and spleen. Peak accumulation of the liposomes in the tumor occurred at 8 h post-injection. Multispectral optoacoustic tomographic imaging was able to provide high-resolution 3D images of the tumor and liposome location. Ex vivo analysis showed that non-targeted liposomes accumulated in the liver, suggesting that specificity of the liposomes for pancreatic adenocarcinoma was due to the presence of the Syndecan-1 ligand.

conclusionsThis study demonstrated that Syndecan-1 liposomes were able to release cargo into IGF1-R expressing tumor cells. The Syndecan-1 liposomes demonstrated tumor specificity in orthotopic pancreatic cancer as observed using multispectral optoacoustic tomography with reduced kidney and liver uptake. By targeting the liposome with Syndecan-1, this nanovehicle has potential as a targeted theranostic nanoparticle for both drug and contrast agent delivery to pancreatic tumors.

Indexed as

AdenocarcinomaAnimalsContrast MediaDrug Delivery SystemsFemaleFluorescent DyesGene ExpressionHumansLiposomesMiceMice, SCIDNeoplasm TransplantationPancreatic NeoplasmsPhotoacoustic TechniquesProtein BindingReceptors, SomatomedinContrast MediaFluorescent DyesLiposomesReceptors, SomatomedinSyndecan-1

Identifiers

PMID26627455
PMCPMC4665906
OpenAlexW2185124674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.